Neuland's first peptide module is operational; a second of up to 18,000L waits on customer specs

The more forward-looking part of the release concerns module two. Foundational infrastructure is already in place, and Neuland says it expects to begin work ahead of the original timeline once customer requirements are finalised — configuration, instrumentation and capacity are being defined in close collaboration with the customer whose projects will anchor the expanded capability. As planned, module two would provide an overall reactor capacity of up to 18,000L: three 5,000L LPPS reactors, either a 1,000L or 2,000L SPPS reactor, and smaller reactors of up to the 1,000L scale. After the $30 million spent on module one, the company says further investment for subsequent modules is being aligned with new customer requirements — in other words, capacity follows contracts, not the reverse.

On demand, the release states that the range of partner indications is broadening beyond obesity and metabolic disease, with oncology emerging as a particularly active area of early-stage development, and that a growing number of biotech companies are struggling to access capable outsourced development and commercial manufacturing capacity. For scale context, the same release puts Neuland's combined reactor capacity across its three US FDA and EU GMP-compliant facilities at approximately 1,218kL — so the 7kL peptide module is small against the company's total installed capacity, but it is a different kind of chemistry from the API base, which is the point of the expansion. That framing is the company's own; whether the demand it describes converts into contracted volumes is what the next few quarters will have to show.

The filing record around these events fills in the operating backdrop. On July 31 the company informed the exchange it had commenced commercial production of additional capacities under its expansion plans at Unit 1 (Bonthapally, Telangana) and Unit 3 (Gaddapotharam, Telangana). On August 14 it disclosed that the US FDA had inspected Unit 3 from August 10–14 and issued a Form 483 with one observation, which the company describes as pertaining to procedural improvements in water and environmental monitoring to include organisms beyond those listed in the US Pharmacopeia; a response is due within stipulated timelines (the stock closed +1.5% on Aug 17, the first session after that filing). On the ownership side, Malabar India Fund disclosed under SAST Regulation 29(2) the sale of 2,72,634 equity shares in the secondary market (filed Aug 17), while the promoter stake was essentially unchanged quarter over quarter — 32.62% as of June 30, 2026 versus 32.63% as of March 31.

The defining move came on August 6, the first session after the Q1 FY27 results: +8.0% on 9,29,534 shares — more than fifteen times the prior session's 60,067 — followed by another +6.1% on August 7. Since then the stock has plateaued between roughly ₹22,500 and ₹24,000; the adjusted 52-week high stands at ₹24,225, dated September 9. Over the sixty sessions in view the stock is up about 31% (₹17,224 on June 22 to ₹22,530), and it has nearly doubled from the March 23 adjusted low of ₹11,500. Tuesday's −4.3% close-to-close move, in the session the peptide release hit the exchange, reads against that backdrop: the announcement landed on a stock already priced within 7% of its high.

Q1 FY27 revenue of ₹641.6 crore against ₹292.8 crore a year earlier is the growth the press release leans on — it attributes the rise chiefly to increased commercial contracts, alongside a growing number of clinical projects. Net profit went from ₹13.9 crore to ₹147.7 crore over the same comparison, with operating margin moving from 11.8% to 34.7%. Two things temper the headline. First, the base quarter (Q1 FY26) was by far the weakest in the table, which flatters the growth rate. Second, the quarters swing widely — ₹40.6 crore of profit in Q3 FY26 next to ₹212.7 crore in Q4 — so single-quarter comparisons over- and under-state the trend in turn. Summing the last four quarters gives roughly ₹497.8 crore of trailing profit; at the ≈ ₹28,906 crore market cap, the market pays about 58× that trailing figure, a multiple that assumes the capacity now coming online converts to revenue.